This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/526834-germany-vaccine-campaign-pace/
The article has changed 3 times. There is an RSS feed of changes available.
Version 1 | Version 2 |
---|---|
Disappointing trial of German-made CureVac coronavirus vaccine won’t hamper immunization at home – health ministry | Disappointing trial of German-made CureVac coronavirus vaccine won’t hamper immunization at home – health ministry |
(about 2 months later) | |
The unsatisfactory trial results of the German-made Covid-19 vaccine will have no effect on the pace of the national immunization campaign, the country’s government has said. | The unsatisfactory trial results of the German-made Covid-19 vaccine will have no effect on the pace of the national immunization campaign, the country’s government has said. |
“The announcement does not have an impact on the speed of our vaccination rollout,” a German Health Ministry spokesperson said, as cited by Reuters. The spokesperson declined to comment on the results of the study. | “The announcement does not have an impact on the speed of our vaccination rollout,” a German Health Ministry spokesperson said, as cited by Reuters. The spokesperson declined to comment on the results of the study. |
Tubingen-based pharmaceutical firm CureVac revealed the preliminary results of the late-stage trial of its CVnCoV coronavirus vaccine on Wednesday. The vaccine has shown a 47% efficacy rate, which “did not meet pre-specified statistical success criteria,” the company said in a statement. | Tubingen-based pharmaceutical firm CureVac revealed the preliminary results of the late-stage trial of its CVnCoV coronavirus vaccine on Wednesday. The vaccine has shown a 47% efficacy rate, which “did not meet pre-specified statistical success criteria,” the company said in a statement. |
The trial involved around 40,000 volunteers in ten Latin American and European countries. | The trial involved around 40,000 volunteers in ten Latin American and European countries. |
CureVac CEO Franz-Werner Haas said that efficacy may change after the company finishes analyzing the data. The emergence of several coronavirus variants “underlines the importance of developing next-generation vaccines,” Haas said. | CureVac CEO Franz-Werner Haas said that efficacy may change after the company finishes analyzing the data. The emergence of several coronavirus variants “underlines the importance of developing next-generation vaccines,” Haas said. |
Karl Lauterbach, an MP from the Social Democratic Party of Germany, voiced disappointment with the results of the trial. “It’s a shame – the team from Tubingen deserved success,” he tweeted. | Karl Lauterbach, an MP from the Social Democratic Party of Germany, voiced disappointment with the results of the trial. “It’s a shame – the team from Tubingen deserved success,” he tweeted. |
German company BioNTech, which is based in Mainz, developed the BNT162b2 vaccine, and partnered with the US-based pharmaceutical giant Pfizer for trials, logistics and manufacturing. | German company BioNTech, which is based in Mainz, developed the BNT162b2 vaccine, and partnered with the US-based pharmaceutical giant Pfizer for trials, logistics and manufacturing. |
Apart from the Pfizer/BioNTech vaccine, Germany uses the Moderna, AstraZeneca/Oxford and Johnson & Johnson vaccines in its immunization campaign. As of Wednesday, 49.6% of the population have received at least one dose of a vaccine, and 28.8% were fully vaccinated, according to the government. | Apart from the Pfizer/BioNTech vaccine, Germany uses the Moderna, AstraZeneca/Oxford and Johnson & Johnson vaccines in its immunization campaign. As of Wednesday, 49.6% of the population have received at least one dose of a vaccine, and 28.8% were fully vaccinated, according to the government. |
Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |